After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pact

Less than six months after lining up one of the largest biobucks packages in industry history, AstraZeneca is returning to the same Chinese partner for another drug R&D collaboration. The UK pharma giant will see ...